Navigation Links
Asymmetrex Introduces New Contract Service For Producing Greater Numbers of Therapeutic Adult Tissue Stem Cells at Reduced Cost
Date:8/29/2017

Today, Asymmetrex, the Massachusetts based stem cell biotechnology innovator, begins offering a new contract service to support the cell therapy industry’s production of therapeutic adult tissue stem cells. Stem cells are a small sub-population of specialized cells that function to renew and repair the organs and tissues of children and adults. Stem cells from a healthy donor can be transplanted to restore or repair diseased or damaged organs and tissues in patients who are sick or injured.

Stem cell transplant treatments do not require expansion of donor stem cells when a donor with a compatible immune system is available for a patient. However, in general, there are many more patients in need of a transplant than there are immune compatible donors. So, the future ability of stem cell medicine to address the full degree of medical need depends on developing the ability to expand initial donor stem cell populations into larger numbers without loss of their curative properties. Expanded numbers of quality adult tissue stem cells are also needed to support statistically sound clinical trials for continued development of stem cell transplant therapies.

Asymmetrex’s new advance for cell therapy suppliers is the result of the company’s unique proprietary expertise in adult tissue stem cell culture. Its recently patented AlphaSTEM Test™ technology, which is a means to count adult tissues stem cells specifically for the first time, is based on the earlier discovery that during expansion in culture, ironically, adult tissue stem cells are lost as a result of their intrinsic tissue renewal property. Under typical culture conditions, stem cells continuously produce non-stem cells that subsequently undergo significant, though limited, multiplication. However, as in the body, stem cells do this while not multiplying their own number. The result of these continued natural processes in culture is progressive dilution and loss of the stem cells with each subsequent expansion culture.

Recently, Asymmetrex demonstrated that not only can its AlphaSTEM Test™ technology be used to count and certify the quality of adult tissue stem cells, but it can also be used to establish unique culture conditions projected to reduce stem cell dilution significantly during expansion. Asymmetrex’s Director, James L. Sherley, M.D., Ph.D., shares, “Two years ago when we achieved specific counting, I expected that we would be able to find conditions for increasing stem cell number, too; but even I didn’t anticipate the projected huge savings in production costs!” The company’s projections indicate that it can achieve production of twice as many stem cells as several companies have reported, but require only 5% or less of their production cost. The required culture time is also reduced significantly.

The new service has been developed first for human mesenchymal stem cells, which are found in a variety of tissues including bone marrow, adipose (fat), umbilical cord, and amniotic fluid. These cells are an ideal first focus, as there are many companies worldwide working on their production to supply hundreds of stem cell transplantation clinical trials each year. Asymmetrex plans to also investigate application of the method to other types of adult tissue stem cells, which have been largely dismissed for expansion because their donor populations are not as proliferative as mesenchymal stem cells. Sherley says that blood stem cells are a very important member of this latter group on the Asymmetrex horizon.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D., is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – quantification and production – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and in pre-clinical assays for drug safety. The same technology underpins Asymmetrex's contract service for optimizing manufacturing processes for therapeutic adult tissue stem cells.

Read the full story at http://www.prweb.com/releases/2017/08/prweb14640052.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. At London Predictive Toxicology Summit Asymmetrex Presents New Biotech Solutions For Earlier Identification Of Drugs Toxic To Patients’ Adult Stem Cells
2. New Commentary from Asymmetrex LLC Director Anticipates Forthcoming E-Book on “Stem Cell Genetic Fidelity”
3. Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at Chicago Stem Cell Research Conference
4. Asymmetrex Opens Up 5th World Congress on Cell and Stem Cell Research in Chicago with a Focus on Its New Technologies for Stem Cell Medical Engineering
5. Asymmetrex Interviewed in Anticipation of Presentations at the 14th Annual World Preclinical Congress Focused on Tackling Translation Challenges
6. Asymmetrex Launches a Crowdsourcing Campaign to Introduce New Biomarkers for Counting Previously Elusive Tissue Stem Cells
7. In August Asymmetrex Will Present Details of Its Crowdsourcing Campaign to Determine the Extent of Application of New Technologies for Counting Adult Tissue Stem Cells
8. Asymmetrex Will Discuss the Importance of Adult Tissue Stem Cell Time with 3D Tissue Engineers at the 14th Annual World Preclinical Congress in Boston in June
9. Asymmetrex Introduces “The Third Dimension of Time” to 3D Cell Modelers at the 14th Annual World Preclinical Congress in Boston
10. Asymmetrex’s Crowdsourcing Campaign For Evaluating A First Biomarker for Counting Adult Tissue Stem Cells Is Gaining Momentum
11. Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/18/2018)... LINDA, Calif. (PRWEB) , ... December 18, 2018 , ... ... after a lumpectomy have better quality of life post-treatment versus whole breast irradiation, a ... two — are typically treated with whole breast irradiation after removal of the cancerous ...
(Date:12/13/2018)... ... December 12, 2018 , ... RURO, ... solutions, announces the Limfinity® ML (Machine Learning) addition for its Limfinity® 7 framework. ... within Limfinity® solutions. In the module, trained models make predictions based on user ...
(Date:12/10/2018)... , ... December 10, 2018 ... ... integrated Contract Development and Manufacturing Organization (CDMO) with sites in China and ... cGMP manufacturing, and aseptic fill finish solutions for monoclonal antibody (mAb) and ...
(Date:12/5/2018)... ... December 05, 2018 , ... STRmix™ – sophisticated forensic software capable of ... been used to convict a Wyoming man of third-degree sexual assault, a felony punishable ... to test for DNA on the couch cushions on which the sexual assault was ...
Breaking Biology Technology:
(Date:12/19/2018)... ... December 19, 2018 , ... InTouchMD’s flagship product, Pulse , has ... 2018. , PM360 is featuring the recognition in its 7th annual Innovations issue, ... to the pharmaceutical and medical device industries. , “This recognition comes at an exciting ...
(Date:12/14/2018)... ... December 14, 2018 , ... ... entitled “Method and System for Microbiome-Derived Diagnostics and Therapeutics” by the US Patent ... 21, 2014. The patent is an invention by uBiome collaborators Dr. Zachary Apte, ...
(Date:12/13/2018)... ... December 12, 2018 , ... New research by Florida Polytechnic University ... drowsy and distracted driving, one of the main causes of car accidents and fatalities ... Dr. Kanwal Gagneja , assistant professor of computer science, uses a microcomputer, a camera, ...
Breaking Biology News(10 mins):